Dabur India Ltd. — Board/Management Information 2019

Jul 19, 2019

==> picture [90 x 91] intentionally omitted <==

==> picture [75 x 48] intentionally omitted <==

==> picture [92 x 91] intentionally omitted <==

==> picture [94 x 46] intentionally omitted <==

==> picture [47 x 8] intentionally omitted <==

Sl.No.	I Particulars	I Particulars	Disclosures
1.	Reason	for	Appointment as additional director in the category of Non- Executive
	change		Promoter Director on the Board of the Company
2.	Date	of	Appointment as additional director in the category of Non- Executive
	appointment		Promoter Director of the Company with effect from July 19, 2019,
	and terms of		subject to approval of shareholders of the Company at the ensuing
	appointment		Annual General meeting
3.	Brief profile		Mr Aditya Burman returned to India after completing his studies in 2003 and
			joined as an intern at Dabur Pharma Limited, a family-owned Oncology-
			focussed Pharmaceutical firm. Fuelled with grit and perseverance, Aditya
			worked towards expanding the company's footprint in the overseas markets
			and was soon in charge of its Sales and Marketing in Latin America. Under his
			stewardship, Dabur Pharma emerged as a leading research-driven
			pharmaceutical firm with a global presence. The company was subsequently
			sold to Fresenius Kabi in 2008.
			He is also a Director on the board of Oncquest Laboratories Ltd., a Clinical
			Pathology and Molecular Diagnostics company with a focus in Oncology and
			Genetics. After the sale of Dabur Pharma, Aditya focussed his energy on
			building Oncquest as the preferred reference laboratory for physicians,
			hospitals and research bodies. He was also instrumental in streamlining
			operations, strengthening its research function, and giving it a pan-lndia
			presence to drive growth.